Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis

NCT07010159 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals International, plc as lead sponsor.

NCT NCT07010159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07010159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 25, 2025
Completion date
December 31, 2029
Enrollment
325 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

pericarditis, pericarditis acute, recurrent pericarditis